TABLE 4

Clinical Characteristics of Patients Who Had and Who Did Not Have Sudden Death

CharacteristicDid not have sudden death (n = 195)Had sudden death (n = 13)P
Age (y)68 ± 1171 ± 110.454
Sex, male120 (61.2%)10 (76.9%)0.379
Ischemic etiology83 (42.6%)6 (46.2%)0.782
NYHA (baseline), I/II/III/IV0/66/108/210/4/5/40.792
NYHA (follow-up), I/II/III/IV38/82/74/12/4/7/00.094
123I-MIBG scintigraphy
 Baseline % denervation59 ± 1159 ± 80.944
 Baseline H/M ratio167 ± 20157 ± 240.106
 Baseline WR (%)48 ± 1156 ± 90.008
 Second % denervation51 ± 1466 ± 13<0.001
 Second H/M ratio178 ± 24146 ± 22<0.001
 Second WR (%)44 ± 1268 ± 8<0.001
 Δ-% denervation−8 ± 128 ± 10<0.001
 Δ-H/M ratio11 ± 16−11 ± 15<0.001
 Δ-WR (%)−4 ± 1112 ± 10<0.001
Echocardiography
 Baseline LVEDV (mL)183 ± 43186 ± 270.762
 Baseline LVESV (mL)124 ± 41138 ± 370.241
 Baseline LVEF (%)33 ± 827 ± 100.013
 Second LVEDV (mL)167 ± 50199 ± 450.026
 Second LVESV (mL)106 ± 48145 ± 540.005
 Second LVEF (%)38 ± 1129 ± 110.002
 Δ-LVEDV (mL)−16 ± 3212 ± 260.003
 Δ-LVESV (mL)−18 ± 327 ± 230.005
 Δ-LVEF (%)6 ± 82 ± 40.106
Pharmacotherapy
 ACE inhibitor130 (66.7%)7 (53.8%)0.374
 ARB127 (65.1%)7 (53.8%)0.551
 β-blocker88 (45.1%)4 (30.8%)0.313
 Spironolactone77 (39.5%)5 (38.5%)0.942
  • Values are mean ± SD or number followed by percentage in parentheses.